DNA damage and repair in normal and neoplastic cells treated with adriamycin. | Zendy

Elżbieta Anuszewska | Zendy; Beata Gruber | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

DNA damage and repair in normal and neoplastic cells treated with adriamycin.

Author(s) -

Elżbieta Anuszewska,

Beata Gruber

Publication year - 1994

Publication title -

acta biochimica polonica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.452

H-Index - 78

eISSN - 1734-154X

pISSN - 0001-527X

DOI - 10.18388/abp.1994_4682

Subject(s) - microgram , dna , dna damage , microbiology and biotechnology , chemistry , cytotoxicity , dna repair , anticancer drug , cell , cell culture , dna synthesis , doxorubicin , drug , cancer research , biochemistry , biology , pharmacology , in vitro , chemotherapy , genetics

Adriamycin (ADR), a common antineoplastic drug, was used to study DNA repair synthesis, cell cytotoxicity and DNA single strand breaks in normal human fibroblasts--CLV98 and human melanoma cells--ME18. No repair synthesis was observed in ME18 and CLV98 cells exposed to adriamycin in concentrations up to 10(-5) M. ME18 cells were less sensitive to ADR treatment than CLV98 cells. Adriamycin-induced DNA single strand breaks (at ADR concentration: 1 microgram/ml) were incompletely repaired in ME18 cells and unrepaired in CLV98 cells within 24 h after drug removal. Within 48 h strand breaks were completely repaired in both kinds of cells. No repair of single strand breaks was observed in ME18 and CLV98 cells after drug treatment in the concentration of 5 micrograms/ml.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research